2025· Proceedings of the 3rd International Conference on Data Analysis and Machine Learning· pp. 347-351· 0 citations· 9 references
TL;DR
This review synthesizes recent work on breast tumor classification with an emphasis on logistic regression and compares it with Support Vector Machines, Decision Trees, XGBoost, and Neural Networks to discuss practical challenges — including interpretability, privacy, dataset shift, and external validation.
Abstract
: Breast cancer is routinely encountered in screening programs and continues to impose a heavy burden on health systems. Shifting diagnosis toward earlier stages is the primary driver of mortality reduction in screening, yet traditional diagnostic pathways — mammography interpretation, ultrasound/MRI assessment, and biopsy — can be expensive, invasive, and vulnerable to human error. Machine learning (ML) is used to prioritize borderline cases and to assign calibrated malignancy risk for expedited review. Among many algorithms, logistic regression (LR) stands out for its simplicity, computational efficiency, and interpretability, which are critical for clinical acceptance. This review synthesizes recent work on breast tumor classification with an emphasis on LR and compares it with Support Vector Machines (SVM), Decision Trees (DT), XGBoost, and Neural Networks (NN). This paper summarizes common datasets and metrics, highlight reported performance ranges, and discuss practical challenges — including interpretability, privacy, dataset shift, and external validation. This paper concludes with suggestions for future research on explainable AI, multi‑modal feature fusion, and privacy‑preserving learning pipelines that are suitable for real‑world healthcare deployments.
Background: Breast cancer is the leading cause of cancer-related mortality in females, with 2.3 million new cases diagnosed annually. Machine learning (ML) algorithms have the potential to improve diagnostic accuracy through the analysis of high-dimensional data. However, the lack of standardized benchmarks across diff...
Ali A. Hamad, Naaman Omar· Charmo Journal of Natural Sc...· 0 citations
Breast cancer is one of the leading causes of cancer-related mortality worldwide, and despite advances in clinical diagnosis, challenges such as inconclusive imaging results and inter-observer variability highlight the need for complementary computational approaches to support early and accurate detection. In this stud...
Early and accurate diagnosis of breast cancer has a direct bearing on patient survival, yet interpretation of fine needle aspirate (FNA) imaging features still depends heavily on clinician experience and remains subject to inter-observer disagreement. This paper presents an empirical case study evaluating two supervise...
Abdul Aziz· Street Art & Urban Creat...· 0 citations
This study bridges the translational gap between predictive accuracy and clinical utility by developing an explainable artificial intelligence (XAI) framework specifically designed for breast cancer diagnosis in underserved healthcare settings, and delivers a reproducible, transparent framework whose SHAP-derived signa...
Oluwaseun Adebayo Bamodu, Sumaiya Nezam, C. Chung· PLOS Digital Health· 0 citations
Breast cancer remains one of the most commonly diagnosed malignancies worldwide, and timely, accurate discrimination between benign and malignant breast masses is critical to reducing unnecessary biopsies while ensuring early treatment of true malignancies. This study presents a comprehensive, methodologically rigorous...
R. Agarwal, Divyansh Mishra, R. Mishra· International Journal of Onc...· 0 citations
The proposed framework can serve as an intelligent decision-support tool for prioritizing breast cancer patients and improving resource allocation when healthcare capacity is constrained and its relatively simple and scalable architecture facilitates potential implementation in healthcare environments with limited reso...
Fabián Silva-Aravena, J. Morales, Hugo Núñez Delafuente et al.· Bioengineering· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.